Normal Tissue Responses to Radiation Therapy

Abstract

AFTER the introduction of supervoltage equipment into clinical practice some 25 years ago, radiation therapy assumed an increasingly prominent role in the management of patients with cancer. Current estimates are that 50 per cent of patients with cancer will receive radiation therapy at some time during the course of their disease, and a large percentage of these patients will be treated with curative intent. Survival rates approximating 90 per cent are reported by many centers treating early seminoma of the testis, Hodgkin's disease, and cancers of the larynx and cervix. Impressive results have recently been reported in prostatic cancer¹ and . . .